The forkhead associated (FHA) domain-containing protein Smad nuclear interacting protein 1 (SNIP1) has multiple cellular functions, including the ability to interact with DNA-binding transcription factors and transcriptional coactivators. Moreover, we have demonstrated previously that SNIP1 regulates cyclin D1 expression and promoter activity. Here, we identify a new function for SNIP1 as a regulator of ATR checkpoint kinasedependent pathways in human U-2 OS osteosarcoma cells: SNIP1 is required for p53 induction in response to ultraviolet light treatment and selectively regulates the phosphorylation of known ATR target proteins, including p53, Chk1 and the histone variant H2AX. These activities are independent of its ability to regulate cyclin D1 expression. Significantly, SNIP1 is also required for ATR-dependent functions of the human p14 ARF tumour suppressor, including its ability to modulate the activity of the RelA(p65) NF-jB subunit. This, together with its other described functions, suggests that SNIP1 could have an important role during tumorigenesis and cancer therapy.
Introduction
Many proteins with forkhead associated (FHA) domains have important roles as regulators of the DNA-damage response, the cell cycle and apoptosis. (Durocher and Jackson, 2002) . Examples of proteins containing FHA domains include the forkhead transcription factors, checkpoint kinase 2 (CHK2), the product of the Nijmegen breakage syndrome gene (NBS1), mediator of DNA damage checkpoint protein 1 (MDC1), kinesins and Chfr, a protein with prophase checkpoint activity (Durocher and Jackson, 2002) . The FHA domain itself is a phospho-threonine peptide-binding motif, although some FHA domains can also bind other phosphorylated residues (Liao et al., 1999; Durocher et al., 2000; Li et al., 2002) . Over 200 FHA domain-containing proteins have been identified and the functions of many remain obscure (Durocher and Jackson, 2002) .
Smad nuclear interacting protein 1 (SNIP1) is a ubiquitously expressed mammalian protein, containing an FHA domain, originally identified through yeast two-hybrid analysis as a Smad transcription factor interacting protein (Kim et al., 2000) . Subsequent studies have also demonstrated potential interactions with the p300 coactivator proteins and BRG1, a component of the ATP-dependent chromatin remodelling complex, Swi/Snf (Kim et al., 2000 (Kim et al., , 2001 Roche et al., 2004) . In the case of p300, this interaction appears to be cell-type-specific, suggesting that the ability of SNIP1 to interact with multiple transcriptional regulators may be regulated by posttranslational modification (Roche et al., 2004) . However, a target-binding sequence for the SNIP1 FHA domain has yet to be identified. Previously, we identified SNIP1 as an important regulator of the cell cycle (Roche et al., 2004) . Depletion of SNIP1 results in downregulation of cyclin D1 expression and promoter activity. This effect required the (AP) (activator protein)-1-binding site of the cyclin D1 promoter. Further underlining a role for SNIP1 in cell cycle progression, SNIP1 expression is induced in the G1 phase of the cell cycle following serum starvation and stimulation. Ectopic expression of SNIP1 also inhibits dorsal mesoderm formation in Xenopus laevis (Kim et al., 2000) . The putative Caenorhabditis elegans SNIP1 homolog (gene name C32E8.5) shows 47% overall homology (www.wormbase.org). RNA interference analysis has demonstrated that loss of C. elegans SNIP1 resulted in embryonic lethality. Furthermore, knockdown of SNIP1 in adult worms resulted in growth defects and sterility (www.wormbase.org/db/gene/gene? name ¼ C32E8.5).
Together, these results indicate an important role for SNIP1 as a regulator of cell viability, growth and proliferation. However, much remains unknown about the mechanisms through which SNIP1 is able to exhibit these effects. In this report, we have extended our analysis of SNIP1 function. We find that SNIP1 also has a role in the DNA-damage response and is a specific regulator of ATR (ataxia telangiectasia-mutated (ATM) and Rad3-related) checkpoint kinase-dependent pathways.
Results
SNIP1 is required for p53 induction by ultraviolet light and the ARF tumour suppressor Many FHA domain-containing proteins are involved in the DNA-damage and repair responses (Durocher and Jackson, 2002) . To investigate any potential role for SNIP1 in these processes, we initially investigated whether loss of SNIP1 would affect induction of the p53 tumour suppressor protein following ultraviolet light (UV-C) treatment of U-2 OS human osteosarcoma cells. Interestingly, small interference RNA (siRNA)-mediated downregulation of SNIP1 significantly inhibited UV-induced p53 protein levels and serine 15 phosphorylation ( Figure 1a) . To determine the generality of this effect, we investigated the effect of SNIP1 loss on the ability of the ARF tumour suppressor and the chemotherapeutic drug and topoisomerase II inhibitor doxorubicin (adriamycin) to induce p53. Knockdown of SNIP1 in NARF2 cells, which are a U-2 OS cell derivative containing a stably integrated, iropropyl-b-Dthiogalaetopyranoside (IPTG) inducible human p14 ARF expression plasmid, inhibited ARF induction of p53 protein levels and the p53 target gene p21 WAF/CIP1 (Figure 1b) . Furthermore, suppression of SNIP1 also inhibited p53 transcriptional activity in a luciferasebased reporter assay (Figure 1c) . By contrast, suppression of SNIP1 did not inhibit induction of p53 by doxorubicin (Figure 1d ). Different forms of genotoxic stress differentially activate the ATM (ataxia telangiectasia-mutated) and ATR checkpoint kinases: UV-C is known to induce preferentially ATR activity, whereas doxorubicin will induce ATM activity (Abraham, 2001; Lin et al., 2001; Motoyama and Naka, 2004) . Moreover, we recently found that ARF-mediated induction of p53 is, in part, ATR-dependent in NARF2 cells (Rocha et al., 2005) . These observations suggested, therefore, that SNIP1 might function as a modulator of ATR activity.
Regulation of the RelA(p65) NF-kB subunit by ARF is also SNIP1-dependent We have previously demonstrated that ARF-induced phosphorylation of RelA on Thr505 is required for ARF-mediated inhibition of RelA transcriptional activity (Rocha et al., 2003a (Rocha et al., , 2005 . Furthermore, these effects are also dependent upon ATR and Thr505 is a substrate for Chk1 (Rocha et al., 2005) , another SNIP1 regulates ATR KC Roche et al checkpoint kinase activated by ATR (Abraham, 2001; Bartek and Lukas, 2003; Motoyama and Naka, 2004) . We reasoned, therefore, that SNIP1 might also be required for the ATR-dependent repression of RelA activity by ARF. Consistent with this hypothesis, overexpression of SNIP1 repressed a Gal4 fusion with the RelA transcriptional activation domain (TAD) in a Thr505-dependent manner ( Figure 2a ) and furthermore, this effect was prevented either by treatment with caffeine, an ATR inhibitor, Go¨6976, a Chk1 inhibitor (Rocha et al., 2005) or cotransfection with kinase dead, dominant-negative ATR or Chk1 expression plasmids ( Figure 2b ). We have demonstrated previously that these inhibitors all similarly reverse ARF-mediated repression of the RelA transactivation domain (Rocha et al., 2003a (Rocha et al., , 2005 . The very low levels of Gal4 RelA plasmid used in this experiment prevented detection of the Gal4 RelA fusion protein by Western blot under the exact experimental conditions used (data not shown). It was therefore impossible to ascertain whether these results might reflect an effect of SNIP1 on RelA stability rather than transactivation function, although the effects of the T505A mutant and ATR/Chk1 inhibition demonstrate that this effect is specific. When expressed at higher levels, a non-specific inhibition of both Gal4
RelA and Gal4 RelA T505A by SNIP1 is seen (data not shown). In addition to not correlating with the functional data this might also reflect problems when coactivators and transcriptional regulators become limiting when higher quantities of plasmid are used. Cotransfection of SNIP1 siRNA expressing plasmids had the opposite effect to SNIP1 overexpression, with Thr505-dependent induction of RelA TAD activity being observed (Figure 2c ). Importantly, SNIP1 siRNA A total of 1 mg of Gal4 E1B luciferase reporter plasmid was transfected into U-2 OS cells together with expression plasmids encoding either Gal4 alone (0.75 ng), Gal4 RelA (TAD) (0.75 ng) or Gal4 RelA (T505A) (0.75 ng). Where indicated, cells were also cotransfected with 1 mg of either a control plasmid or SNIP1 expression plasmid. In (b), cells were also treated with 2 mM caffeine, 1 mM Go¨6976 or cotransfected with 1 mg of kinase dead, dominant-negative ATR (KD-ATR) or Chk1 (KD-Chk1) expression plasmids. (c) SNIP1 is required for ARF-mediated repression of the RelA TAD. A total of 1 mg of Gal4 E1B luciferase reporter plasmid was transfected into NARF2-E6 cells together with expression plasmids encoding either Gal4 alone (0.75 ng), Gal4 RelA (TAD) (0.75 ng) or Gal4 RelA (T505A) (0.75 ng). Where indicated, cells were also cotransfected with either 3 mg of a control siRNA expression plasmid or 1 mg each of three SNIP1 siRNA plasmids (3 mg total). ARF was induced for 24 h. (d) SNIP1 is required for ARF-induced repression of the Bcl-xL promoter. A total of 1.5 mg of the Bcl-xL or Bcl-xL DkB luciferase reporter plasmids were transfected into NARF2-E6 cells together with either 3 mg of a control siRNA expression plasmid or 1 mg each of three SNIP1 siRNA plasmids (3 mg total). In this luciferase assay, results are expressed as fold activation or repression, relative to levels seen in the relevant untreated cell controls. SNIP1 regulates ATR KC Roche et al treatment also prevented ARF-mediated repression of the RelA TAD (Figure 2c ). Similar effects could also be seen with endogenous NF-kB activity in U-2 OS cells. SNIP1 siRNA induced Bcl-xL promoter activity, in a kB-site-dependent manner, using a luciferase reporter gene assay (Figure 2d ). Bcl-xL is a wellestablished NF-kB target gene which we have previously shown to be regulated by RelA in U-2 OS and NARF2 cells (Chen et al., 2000; Rocha et al., 2003a; Campbell et al., 2004) . Importantly, repression of endogenous Bcl-xL mRNA expression by ARF was also SNIP1-dependent (Figure 2e ). Significantly, SNIP1 does not abolish UV-C induced repression of Bcl-xL, which we have found to be ATR-independent (Campbell et al., 2004) . Together, these results suggest that through functioning as a regulator of ATR, SNIP1 can also control aspects of ARF tumour suppressor function.
SNIP1 is required for H2AX phosphorylation
A growing group of proteins have been shown to function as regulators of checkpoint kinase substrate specificity. These include BRCA1 and NBS1, which are required for Chk1 and p53 phosphorylation by ATR and ATM but do not significantly affect phosphorylation of the histone variant H2AX (gH2AX), which is a marker for sites of DNA damage (Redon et al., 2002; Foray et al., 2003; Lowndes and Toh, 2005; Stiff et al., 2005) , and Pax2 transactivation domain-interacting protein (PTIP), which is required for ATM regulation of p53 (Jowsey et al., 2004) . Immunofluorescence and Western-blot analysis demonstrated that SNIP1 depletion also inhibits UV-C-induced H2AX phosphorylation (Figures 3a and b , and also 4b). Furthermore, the phosphorylation of the ATR target Chk1, at serine 345, is also inhibited (Figure 3c ). SNIP1 levels did not significantly affect the levels of ATR or the ATRinteracting protein, ATRIP (Cortez et al., 2001 ) (Figure 3c ), although effects on other ATR adaptor proteins cannot be ruled out. Interestingly, knockdown of ATR, which also inhibited UV-induced p53 activation and Chk1 phosphorylation, resulted in depletion of ATRIP protein, as has been reported previously (Cortez et al., 2001) . A selective role for SNIP1 as an ATR modulator was indicated by analysis of SMC1, another ATR target (Wang and Qin, 2003; Syljuasen et al., 2005) , where SNIP1 knockdown had a minimal effect on its UV-C-induced phosphorylation (Figures 3b and  also 4b ). ATR-dependent phosphorylation of SMC1 has previously been shown to function through a pathway distinct to that required for Chk1 phosphorylation (Wang and Qin, 2003) . Interestingly, analysis of the effect of SNIP1 depletion of p53 and H2AX over a time course demonstrated more pronounced effects at earlier time points (Figure 4a) . Indeed, after 6 h, the effects of SNIP1 depletion are no longer noticeable. This again indicates that SNIP1 modulates ATR function and is not absolutely required for its activity.
SNIP1 effects on ATR do not result from repression of cyclin D1 expression
When analysing SNIP1 effects, a potentially complicating factor is that depletion of SNIP1 results in loss of cyclin D1 expression (Roche et al., 2004) . Therefore, it was important to verify whether any effects attributed to SNIP1 are merely a secondary consequence of downregulation of cyclin D1 depletion. To investigate this, we employed a cyclin D1 siRNA to mimic that aspect of SNIP1 function. Although, as we have reported previously (Roche et al., 2004) , knockdown of SNIP1 leads to a moderate increase in cells in G1 phase, this is less pronounced than that seen with the cyclin D1 siRNA (Supplementary Figure 1) , although neither treatment leads to a dramatic decrease in S or G2 phase cells over this time course. Importantly, under the same siRNA treatment conditions, cyclin D1 depletion did not significantly affect UV-C-induced induction of p53 or phosphorylation of H2AX and SMC1. Similarly, loss of cyclin D1 did not significantly affect ARF-induced p53 activity (Figure 4c ). Of note, as we have reported previously (Rocha et al., 2003b) , UV-C treatment alone results in repression of cyclin D1 expression. The critical effect being tested here, however, is the consequence of loss of cyclin D1 before UV-C stimulation.
SNIP1 associates with ATR
As SNIP1 regulates ATR-dependent pathways, we next investigated whether SNIP1 can associate with ATR. Coimmunoprecipitation analysis from U-2 OS cell protein extracts demonstrated that while an interaction can be seen, only a low level of endogenous ATR is SNIP1-associated and this interaction is unaffected by UV-C stimulation (Figure 5a ). Transfection of an hemaglutinin (HA) tagged SNIP1 expression plasmid into HEK293 cells and subsequent coimmunoprecipitation analysis confirmed that SNIP1 and ATR can interact (Figure 5b) . Interestingly, transfection of HAtagged SNIP1 deletion mutants revealed that the interaction was specific for the FHA-domain containing C-terminal region of SNIP1 (Figure 5b ). By comparison, it is the N-terminal region of SNIP1 that has been previously shown to interact with the p300 coactivator and bind RelA in vitro (Kim et al., 2000 (Kim et al., , 2001 . Importantly, gel filtration analysis demonstrated that neither ATR nor Chk1 is present in the high-molecularweight SNIP1 complex we identified previously (Roche et al., 2004) (Figure 5c ), suggesting that this interaction is weak and likely to be transient. However, it should be noted that ATR and Chk1, which clearly can interact in cells, also do not significantly co-elute in this assay. Immunofluorescence data indicated a low level of colocalization of SNIP1 and ATR (Supplementary Figure 2) . Although consistent with a transient or modulatory association, the degree of colocalization was too weak to draw firm conclusions or provide insight into how SNIP1 regulates this pathway ( Supplementary  Figure 2) . Moreover, SNIP1 did not significantly colocalize with gH2AX staining, ATRIP or BRCA1 (Supplementary Figure 2) .
Discussion
In this report, we identify SNIP1 as a regulator of ATRdependent pathways. Downregulation of SNIP1 protein prevents induction and phosphorylation of p53 and other known ATR target proteins. SNIP1 appears functionally distinct to previously described ATR regulatory proteins such as BRCA1, NBS1 and PTIP: it is required for p53, Chk1 and H2AX phosphorylation and its effects appear specific for ATR rather than ATM. SNIP1 also appears to be required for multiple inducers of ATR activity. In addition to UV-C and ARF-induced activity shown here, we have also observed a requirement for hydroxyurea-induced ATR activity (data not shown). However, a wider array of DNA-damaging agents will need to be analysed before it can be definitively concluded that SNIP1 does not regulate ATM. Nonetheless, the ability of SNIP1 to phosphorylation. Immunofluorescence analysis of SNIP1 and gH2AX following UV-C treatment (a). U-2 OS cells, treated either with a control or SNIP1 siRNA, were plated onto coverslips and fixed 4 h after exposure to UV-C or after no treatment. Cells were stained with the 2B12 anti-SNIP1 monoclonal antibody or gH2AX antibody as indicated. Western-blot analysis of gH2AX and SMC1 phosphorylation in U-2 OS cell whole cell lysates following UV-C stimulation and/or treatment with control or SNIP1 siRNAs (b).
(c) Analysis of ATR substrates following UV-C and SNIP1/ATR siRNA treatment. Western-blot analysis of p53 and Chk1 phosphorylation in U-2 OS cell whole cell lysates following UV-C stimulation and/or treatment with control or SNIP1 or ATR siRNAs. Also shown are ATR, ATRIP and SNIP1 expression levels following siRNA treatment and/or UV-C stimulation.
regulate ATR-dependent pathways is consistent with the known roles of FHA domain-containing proteins, a number of which have previously been identified as adaptors and integrators of the DNA damage and checkpoint responses (Durocher and Jackson, 2002) . Whether SNIP1 can integrate ATR activity with the other pathways it regulates or whether these represent separate and distinct functions will require further investigation. Only a relatively small proportion of SNIP1 and ATR can be seen to coimmunoprecipitate, both before and after DNA damage, although overexpression data confirmed that these proteins are able to associate. Moreover, immunofluorescence analysis did not reveal any significant colocalization between SNIP1 and ATR, ATRIP, BRCA1 or gH2AX (Supplementary Figure 2) . These results suggest that SNIP1 is not recruited directly to sites of DNA damage and any interaction with ATR in cells, between endogenous proteins, is probably transient, although it is possible that the epitopes recognized by the antibodies used might be masked under the experimental conditions used or when these proteins are in a complex. In addition, it is quite possible that this interaction is indirect. It is plausible that SNIP1 might facilitate the association of ATR with other regulatory proteins or with select substrates. However, whether the ability of SNIP1 to regulate ATR-dependent pathways results solely from this interaction will require further investigation. For example, although significant effects on ATR or ATRIP expression were not observed, it cannot be ruled out that SNIP1-dependent transcription of an ATR cofactor is the primary mechanism through which its effects on checkpoint signalling are revealed.
We also report that SNIP1 is essential for ARFmediated regulation of the RelA NF-kB subunit (Rocha et al., 2003a (Rocha et al., , 2005 . SNIP1 has previously been implicated as a regulator of NF-kB through binding p300 (Kim et al., 2001) . SNIP1 has also been reported to bind directly to the Rel homology domain (RHD) of RelA (Kim et al., 2001) . However, in this report we also demonstrated SNIP1-dependent effects through the T505 motif of the RelA transactivation domain, a residue required for the effects of ARF (Rocha et al., 2003a (Rocha et al., , 2005 . Potentially, therefore, SNIP1 can regulate RelA and NF-kB activity through multiple mechanisms that will vary dependent upon the context or cell type.
In addition to being required for ARF-dependent effects, SNIP1 also regulates the expression of the cyclin D1 proto-oncogene (Roche et al., 2004) . SNIP1 therefore appears to be able to contribute to fundamentally different pathways. Furthermore, its other described functions are also consistent with a role as a regulated adaptor and integrator of multiple protein complexes. Our preliminary data indicate that SNIP1 is itself phosphorylated (data not shown). Thus SNIP1's function as a key integrator of cellular decision-making processes could be dependent upon its modification status and context. It is interesting that regulators of ATM/ATR activity, such as BRCA1, have important roles in tumour development and cancer therapy. It is too early to predict whether SNIP1 will be an oncogene or tumour suppressor in its own right but it will be of interest to investigate whether SNIP1 expression varies in different tumours and if it might be a marker for differing responses to cancer therapies that rely on inducing DNA damage. (Stott et al., 1998; Rocha et al., 2003a) . These were not grown beyond passage 30. Wild-type U-2 OS cells fail to express ARF due to hypermethylation of its promoter. Where indicated cells were treated with 2 mM doxorubicin or 40 J/m 2 UV-C (254 nm) using a Stratalinker (Stratagene, Amsterdam, Netherlands).
Materials and methods

Cells
Antibodies
The SNIP1 polyclonal rabbit antibodies were raised by Diagnostics Scotland using purified, recombinant His-tagged SNIP1 protein fragments (either amino acids 2-80 or 120-396). The SNIP1 monoclonal antibodies 2B12 and 3D3 were raised using a purified, recombinant His-tagged SNIP1 fragment (amino acids 2-80) by Hybricore GmbH. The 2B12 SNIP1 antibody was used for immunofluorescence studies. The 3D3 SNIP1 antibody was used for Western blots in Figures 3c, 4a-c and 5c.
Other antibodies used in this report were anti p14 ARF (Ab1 RD-045; Neomarkers, Fremont, CA, USA), p21 (sc-397, Santa Cruz, Santa Cruz, CA, USA), ATR (N-19, sc-1887, Santa Cruz), ATM (Ab-3, PC116, Calbiochem, Nottingham, UK), ATRIP (ab19351, Abcam, Cambridge, UK), Chk1 (sc-7898, Santa Cruz), phospho-Chk1 serine345 (2341, Cell Signaling, Beverly, MA, USA), cyclin D1 (556470, Pharmingen, San Diego, CA, USA), b-actin (Sigma, Gillingham, UK), BRCA1 (Ab1 OP92, Calbiochem), g-H2AX (ct07-164, Upstate, Dundee, UK), phospho-p53 serine 15 (9286 and 9284, Cell Signaling) and anti-phospho-SMC1 serine 966 and anti-SMC1 antibodies (BL311 and BL308 respectively; Bethyl Labs, Montgomery, TX, USA). The anti-p53 DO1 antibody was obtained from CR-UK.
Other experimental procedures
All reporter plasmid luciferase assays, Western blots and immunoprecipitations were performed as described previously (Rocha et al., 2003a (Rocha et al., , 2004 (Rocha et al., , 2005 Campbell et al., 2004) . All plasmids, and siRNAs have been described and characterized before (Rocha et al., 2003a (Rocha et al., , 2004 (Rocha et al., , 2005 Campbell et al., 2004) . Luciferase assays were performed according to the manufacturer's instructions (Promega, Southampton, UK), and results were normalized for protein concentration with all experiments performed a minimum of three times before calculating means and standard deviation as shown in the figures. Additional information on siRNA transfections, microscopy, RNA extraction and semiquantitative PCR (polymerase chain reaction) analysis and gel filtration is available as Supplementary Information on the Oncogene website. high-molecular-weight complex. HeLa nuclear protein extract was resolved by Superose 6 gel filtration. Fractions were collected and resolved by SDS-PAGE followed by immunoblotting for SNIP1, ATR and Chk1. The positions of molecular weight markers used during column calibration are shown.
